In prescription pharmaceuticals, Taisho is implementing a structure to continuously create new drugs for domestic and overseas use. In research and development, Taisho conducts in-house programs and develops tie-ups with corporations and research facilities in Japan and overseas. Taisho's independent development system in the U.S. was begun with the establishment of the subsidiary Taisho Pharmaceutical R&D Inc. in New Jersey in August 2001. We reinforced our network for gathering information from research centers in Japan, the United States and Europe to stay abreast of the latest information in pharmaceutical research. New computer-based technologies, such as genome analysis and sequence determination, high throughput screening and combinatorial chemistry, have significantly improved the quality and speed of new drug development. In an initiative begun in 1995, Taisho is shifting to a business model in order to continuously create candidate substances for new drug development. Taisho Toyama Pharmaceutical Co., Ltd., a sales subsidiary jointly established with Toyama Chemical Co., Ltd., is helping to expand sales channels as we build on our growing expertise in the infectious disease and anti-inflammatory fields. Taisho has completed the organization of a robust sales structure which covers all of Japan.
In prescription pharmaceuticals, Taisho is implementing a structure to continuously create new drugs for domestic and overseas use. In research and development, Taisho conducts in-house programs and develops tie-ups with corporations and research facilities in Japan and overseas. Taisho's independent development system in the U.S. was begun with the establishment of the subsidiary Taisho Pharmaceutical R&D Inc. in New Jersey in August 2001. We reinforced our network for gathering information from research centers in Japan, the United States and Europe to stay abreast of the latest information in pharmaceutical research. New computer-based technologies, such as genome analysis and sequence determination, high throughput screening and combinatorial chemistry, have significantly improved the quality and speed of new drug development. In an initiative begun in 1995, Taisho is shifting to a business model in order to continuously create candidate substances for new drug development. Taisho Toyama Pharmaceutical Co., Ltd., a sales subsidiary jointly established with Toyama Chemical Co., Ltd., is helping to expand sales channels as we build on our growing expertise in the infectious disease and anti-inflammatory fields. Taisho has completed the organization of a robust sales structure which covers all of Japan.
